Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.2452W HIGH $12.54
Volume
4.56 M
Value Traded
27.08 M
Short % Float
24.99%
Days to Cover
9.0
+21.24%Week
+3.34%1 Month
+43.06%3 Month
+126.22%6 Month
-75.71%5 Year
-75.71%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.91 B
EPS (TTM)
-0.71
P/E Ratio
-
Ent. Value
1.71 B
Total Shares
171.49 M
Float Shares
148.14 M
Insiders
13.68%
Institutions
83.67%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ABSI Catalyst Timeline
Dated clinical, regulatory and corporate events for Absci Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Absci Corporation
137Total events
10Upcoming
37Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Interim AnalysisABS-201Trial
Positive interim Phase 1 data from HEADLINE trial of ABS-201 announced
▼Equity OfferingCorporate
Completed $100 million underwritten offering including $40 million strategic investment from Eli Lilly & Company
▲First Patient DosedABS-201Trial
First MAD cohort dosed in HEADLINE trial
androgenetic alopeciasource ↗
▲Enrollment CompleteABS-201Trial
Completed dosing of all four planned SAD cohorts
androgenetic alopeciasource ↗
▲Development Candidate NominationABS-202Preclinical
Addition of ABS-202 to pipeline
undisclosed inflammation and immunology indicationsource ↗
◆Interim AnalysisABS-201Trial
Potential interim efficacy readout for ABS-201
androgenetic alopeciasource ↗
◆Topline ReadoutABS-201Clinical Data
Preliminary safety, tolerability, and PK data
androgenetic alopeciasource ↗
●Management ChangeCorporate
Retirement of Chief Innovation Officer Andreas Busch effective March 31, 2026
▲First Patient DosedABS-201Trial
First three cohorts dosed in SAD portion of HEADLINE trial
androgenetic alopeciasource ↗
▲Safety Data UpdateABS-201Clinical Data
Favorable emerging safety data from SAD portion
androgenetic alopeciasource ↗
▲Preclinical PoCABS-201Preclinical
Human ex vivo data demonstrating hair growth and follicle stem cell niche regeneration
androgenetic alopeciasource ↗
▲Trial InitiationABS-201Trial
Initiation of Phase 1/2a clinical trial for ABS-201
androgenetic alopeciasource ↗
◆Trial InitiationABS-201Trial
Initiation of Phase 1/2a trial for ABS-201 in androgenetic alopecia
androgenetic alopeciasource ↗
▲Full ResultsABS-101Clinical Data
Interim results for Phase 1 trial of ABS-101 reported
inflammatory diseases (anti-TL1A)source ↗
▲Partnership / LicenseCorporate
Expanded collaboration with Almirall with election of second target
dermatological indicationssource ↗
▼Equity OfferingCorporate
Raised approximately $50 million in gross proceeds from underwritten public offering of common stock
▲First Patient DosedABS-101Trial
Initiated dosing of participants in first-in-human study of ABS-101
healthy volunteerssource ↗
◆Interim AnalysisABS-101Trial
Interim data from Phase 1 study of ABS-101 expected
healthy volunteerssource ↗
◆Topline ReadoutABS-101Clinical Data
Interim data readout for ABS-101 Phase 1
inflammatory disease (anti-TL1A)source ↗
▲Partnership / LicenseCorporate
Strategic collaboration with AMD including $20M equity investment
◆Trial InitiationABS-101Trial
Initiate Phase 1 clinical studies for ABS-101
inflammatory disease (anti-TL1A)source ↗
●IND SubmissionABS-101IND
Expects to submit IND for ABS-101
inflammatory bowel disease (anti-TL1A)source ↗
▲Preclinical PoCABS-101Preclinical
ABS-101 non-human primate PK/PD study data unveiled in January 2025
inflammatory bowel disease (implied)source ↗
●Oral PresentationPresentation
Absci 2024 R&D Day showcasing pipeline updates and platform achievements
▲Development Candidate NominationABS-201Preclinical
ABS-201 development candidate nominated with preclinical profile
androgenic alopeciasource ↗
▲Preclinical PoCABS-101Preclinical
ABS-101 new preclinical data including reduced internalization and PK/PD study results
inflammatory bowel disease (implied by anti-TL1A)source ↗
▲Milestone PaymentCorporate
Delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling first milestone under collaboration
oncologysource ↗
▲Partnership / LicenseCorporate
Entered into collaboration with Twist Bioscience to design a novel antibody using generative AI
●Poster PresentationABS-101Presentation
Poster presentation at Festival of Biologics Europe 2024 on ABS-101
IBDsource ↗
▲Preclinical PoCABS-101Preclinical
Released results from non-human primate studies for ABS-101 demonstrating 2-3x extended half-life
inflammatory disease (anti-TL1A)source ↗
▲Partnership / LicenseCorporate
Entered into collaboration with Memorial Sloan Kettering Cancer Center to co-develop up to six novel oncology therapeutics
oncologysource ↗
Past FDA Catalysts and PDUFA Decisions
How ABSI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | ABS-201 | Phase 1/2a data readout | Phase 1/2a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 71%
Micro Cap(rank 467 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ABS-201 Small moleculeNCT07317544 | Androgenetic Alopecia (AGA) | Phase 1 | RECRUITING | 227 | Jul 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every ABSI program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ABS-201 | androgenetic alopecia | Phase 1/2a | 2026-05-07 | Successfully dosed all four planned healthy volunteer single ascending dose (SAD) cohorts; well tolerated with favorable emerging safety data; preliminary PK modeling supports ABS-201's targeted dosing interval of two or three injections over a six-month periodRead More | Absci Corporation Unaudited Condensed Consolidated Balance Sheets March 31, December 31, (In thousands, except for share and per share data) 2026 2025 ASSETS Current assets Cash and cash equivalents $ 8,627 $ 20,025 MarkRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Szela Mary TDirector | Buy | 12,900 21,300 held | $11.54 | 06/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ABSI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Redmile Group, LLC | 5.2 % (225 %) | 78.11 M | 6.74 M | -18.34% ( -1.51 M) |
ABSI Institutional Ownership Trends
ABSI Short Interest
Shares sold short, counted twice a month.
24.99%
Short % of Float
of tradable shares sold short
37.0M
Shares Sold Short
-1.1% vs prior count
9.0 High
Days to Cover
trading days of normal volume to buy every short share back
4.1M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ABSI ranks across every disease it competes in
Competitive Position is a premium feature
See how ABSI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialABSI News
ABSI▲ +11.9%on this news· ran to +26% by day 1
Absci to Participate in Upcoming Investor Conferences
Absci Corporation announced its participation in several upcoming investor conferences, including the Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference. The company is focused on advancing drug discovery through its Integrated Drug Creation platform, which utilizes generative AI. ABS-201, a key therapeutic, targets hair regrowth and endometriosis.
Read more →ABSI▼ -5.9%on this news
Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026
Absci Corporation will report its business updates and third quarter 2026 financial results on November 12, 2026. A conference call will follow the report to discuss these developments. The company is known for its innovative use of generative AI in drug discovery and has promising therapeutics in its pipeline, including ABS-201.
Read more →ABSI▲ +6.2%on this news
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
Absci Corporation has announced plans for a Phase 2 clinical trial of ABS-201, an AI-designed antibody for treating endometriosis. The trial will evaluate the efficacy and safety of ABS-201 in patients with moderate to severe endometriosis-associated pain. The study is expected to begin in mid-2027, recruiting around 150 patients across multiple countries.
Read more →ABSIAbsci Reports Business Updates and Second Quarter 2026 Financial and Operating Results
Absci reported positive interim Phase 1 data for its ABS-201 trial and completed a $100 million offering, including a $40 million investment from Eli Lilly. The company held $201.1 million in cash and marketable securities as of June 30, 2026. This balance is sufficient to fund operations into the second half of 2028. Net loss for the quarter was $33.2 million.
Read more →ABSIAbsci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
Absci Corporation will report its second quarter 2026 financial and operating results after market close on August 11, 2026. The company plans to host a conference call at 4:30 p.m. Eastern Time to discuss these updates. Investors can access the live webcast through the firm’s investor relations website. The event will also be archived for replay after the initial broadcast.
Read more →ABSI▲ +36%on this news· ran to +53% by day 3
Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors
Absci priced an underwritten offering of 13,495,277 shares at $7.41 per share. The transaction raises approximately $100 million in gross proceeds. Eli Lilly and several financial firms participated in the investment. The company will use the funds to advance its AI-designed antibody program for hair loss and endometriosis.
Read more →ABSI▲ +36%on this news· ran to +53% by day 3shared move
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)
Absci reported positive interim Phase 1 data for ABS-201, an investigational antibody for hair loss. The drug showed a favorable safety profile with no serious adverse events among 32 participants. Researchers estimated a half-life of at least 65 days, supporting a dosing schedule of two or three injections over six months. The company plans to release interim proof-of-concept data in late 2026.
Read more →ABSIAbsci Reports Business Updates and First Quarter 2026 Financial and Operating Results
Absci Corporation reported significant advancements in its clinical trials and pipeline during Q1 2026. The company successfully completed the dosing of its single ascending dose cohorts for the ABS-201 trial, which is targeting androgenetic alopecia, and has initiated dosing of the multiple ascending dose cohort. Financially, Absci faced challenges with a drop in revenue and an increased net loss compared to the previous year, although it believes its financial reserves will sustain operations through mid-2028. The addition of ABS-202 to its pipeline signifies the company’s commitment to expanding its therapeutic offerings.
Read more →ABSIAbsci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Absci Corporation announced the granting of a non-statutory stock option for 276,200 shares to a newly-hired non-executive employee. This inducement grant, approved by the Compensation Committee, is part of Absci's 2023 Inducement Plan and aims to attract talent. The stock option has an exercise price of $4.92 per share and vests over four years.
Read more →ABSIAbsci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026
Absci Corporation will report its business updates and Q1 2026 financial results on May 7, 2026. A conference call will follow to discuss these developments. The company is focused on advancing drug discovery through generative AI and has a promising pipeline, including ABS-201 for hair regrowth and endometriosis.
Read more →ABSIAbsci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results
Absci Corporation reported its fourth quarter and full-year 2025 financial results, highlighting progress in its ABS-201 HEADLINE trial, which has successfully dosed its first three cohorts with favorable safety data. ABS-201 demonstrates potential in treating androgenetic alopecia and endometriosis, both areas with significant unmet medical needs. The company also appointed Dr. Ransi Somaratne as Chief Medical Officer to enhance its clinical strategy. Despite a net loss of $115.2 million for the year, Absci maintains a solid cash position to fund operations into mid-2028.
Read more →ABSI▼ -8.1%on this news
Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer
Absci Corporation has appointed Ransi Somaratne, M.D., FACC, MBA, as its new Chief Medical Officer to lead clinical development efforts. Somaratne, previously with Vertex Pharmaceuticals, brings extensive experience in biopharmaceuticals and will focus on advancing Absci's innovative AI-designed therapeutics pipeline. This transition comes as the company sees rapid progress in its programs, particularly the flagship ABS-201. Additionally, Chief Innovation Officer Andreas Busch will retire in March 2026 but will continue to support the company as co-chair of the Scientific Advisory Board.
Read more →ABSIAbsci Reports Business Updates and Third Quarter 2025 Financial and Operating Results
Absci Corporation announced its financial and operational results for the third quarter of 2025, highlighting its strategic focus on the ABS-201 program for androgenetic alopecia and endometriosis. The company is on track to initiate a Phase 1 trial for ABS-201 in December 2025 and plans to expand its indications. Despite a reported net loss of $28.7 million and declining revenue, Absci maintains a strong cash position, sufficient to fund operations into the first half of 2028. The interim results for ABS-101 also indicated a favorable safety profile, with exploratory partnerships being considered.
Read more →ABSIAbsci Reports Business Updates and Second Quarter 2025 Financial and Operating Results
Absci Corporation reported its financial and operating results for the second quarter of 2025, revealing strong execution and positive developments in clinical trials. The company successfully raised approximately $64 million, ensuring funding through the first half of 2028. Absci also expanded its collaboration with Almirall to include a second dermatological target. Despite a net loss increase and a decline in revenue compared to the previous year, the outlook for ongoing clinical trials remains optimistic with major milestones anticipated in the near future.
Read more →ABSIAbsci Announces Proposed Public Offering of Common Stock
Absci Corporation has announced a proposed underwritten public offering of $50 million of its common stock, with an additional $7.5 million option for underwriters. The funds raised will support the advancement of internally developed programs and investments in its Integrated Drug Creation platform. The offering is contingent on market conditions and the final terms will be outlined in a prospectus supplement to be filed with the SEC. Absci utilizes generative AI to enhance drug creation processes.
Read more →ABSIAbsci Reports Business Updates and First Quarter 2025 Financial and Operating Results
Absci Corporation has reported its first quarter financial results for 2025, highlighting significant progress in its pipeline. The company has initiated a first-in-human study for its ABS-101 antibody, with interim data expected later this year. Additionally, promising non-human primate study results for ABS-201 support its development as a treatment for androgenetic alopecia. Despite reporting a net loss of $26.3 million, Absci's financial status remains strong, with enough cash reserves to sustain operations into mid-2027.
Read more →ABSIAbsci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results Unveiled updates across proprietary pipeline and demonstrated new breakthroughs by AI platform at 2024 R D Day
Absci Corporation reported its financial and operational results for Q4 and the full year of 2024, showcasing advancements in its AI Integrated Drug Creation platform. Notable highlights include the collaboration with AMD resulting in a $20 million investment and the expected initiation of Phase 1 studies for ABS-101. However, the company reported a net loss of $29 million for the last quarter and a decrease in total revenue compared to the previous year. Despite the financial challenges, there are positive prospects for its key therapeutic candidates.
Read more →About Absci Corporation
Headquarters18105 SE MILL PLAIN BLVD, VANCOUVER, WA, 98683
BIOPHARMAWATCH ELITE PLUS
Trade the next ABSI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime